Migraine Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, and Clinical Trials | GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Amgen, Abbvie Inc., AstraZeneca, Eli Lilly and Co

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Migraine pipeline constitutes 30+ key companies continuously working towards developing 30+ Migraine treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Migraine Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Migraine Market.

The Migraine Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Migraine Pipeline Report: https://www.delveinsight.com/sample-request/migraine-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Migraine treatment therapies with a considerable amount of success over the years.
• Migraine companies working in the treatment market are Eli Lilly and Company, Satsuma Pharmaceuticals, Pulmatrix, Vaxxinity, Inc., Tonix Pharmaceuticals, Inc, AEON Biopharma, Inc., Axsome Therapeutics, Pfizer, and others, are developing therapies for the Migraine treatment
• Emerging Migraine therapies in the different phases of clinical trials are- LY3451838, STS-101, PUR-3100, UB-313, TNX-1900, ABP-450, AXS 07, Zavegepant, and others are expected to have a significant impact on the Migraine market in the coming years.
• In March 2024, H. Lundbeck, a biopharmaceutical company, launched the PROCEED Phase IIb investigation to assess the effectiveness and safety of Lu AG09222, a promising therapy for preventing migraines. This study comes after the positive outcomes observed in the HOPE Phase IIa trial, which provided evidence of the efficacy of Lu AG09222 when administered intravenously for migraine prevention.
• In June 2023, Eli Lilly and Company (NYSE: LLY) disclosed the findings from the CHALLENGE-MIG clinical trial, which compared Emgality® (galcanezumab-gnlm) and Nurtec® ODT (rimegepant orally disintegrating tablet), two calcitonin gene-related peptide (CGRP) antagonist therapies. Emgality did not achieve statistical superiority over Nurtec ODT in the primary endpoint of the study, which aimed to determine the percentage of participants experiencing a 50% or greater reduction in monthly migraine headache days. Despite this, Emgality demonstrated clinically significant efficacy and safety during the 3-month trial, consistent with its performance in previous 6-month studies. Moreover, Emgality exhibited better numerical outcomes in key secondary endpoints compared to Nurtec ODT.
• In December 2023, Teva Pharmaceuticals revealed encouraging findings from a retrospective examination of the Phase III HALO-LTS and FOCUS clinical studies, evaluating the effects of Ajovy (fremanezumab) in individuals experiencing migraines alongside obesity-related conditions.

Migraine Overview
Migraine is a neurological disorder characterized by recurring headaches that are often intense and debilitating. These headaches typically affect one side of the head and are often accompanied by other symptoms such as nausea, vomiting, and sensitivity to light and sound. Migraines can last for hours or even days and can significantly impact a person's quality of life.

Get a Free Sample PDF Report to know more about Migraine Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/migraine-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Migraine Drugs Under Different Phases of Clinical Development Include:
• LY3451838: Eli Lilly and Company
• STS-101: Satsuma Pharmaceuticals
• PUR-3100: Pulmatrix
• UB-313: Vaxxinity, Inc.
• TNX-1900: Tonix Pharmaceuticals, Inc
• ABP-450: AEON Biopharma, Inc.
• AXS 07: Axsome Therapeutics
• Zavegepant: Pfizer

Migraine Route of Administration
Migraine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Migraine Molecule Type
Migraine Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Migraine Pipeline Therapeutics Assessment
• Migraine Assessment by Product Type
• Migraine By Stage and Product Type
• Migraine Assessment by Route of Administration
• Migraine By Stage and Route of Administration
• Migraine Assessment by Molecule Type
• Migraine by Stage and Molecule Type

DelveInsight's Migraine Report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Migraine product details are provided in the report. Download the Migraine pipeline report to learn more about the emerging Migraine therapies
https://www.delveinsight.com/sample-request/migraine-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Migraine Therapeutics Market include:
Key companies developing therapies for Migraine are - GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Amgen, Abbvie Inc., AstraZeneca, Eli Lilly and Co., Teva Pharmaceuticals, Novartis AG, Eisai Co., Ltd., Abbott Laboratories, and others.

Migraine Pipeline Analysis:
The Migraine pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Migraine with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Migraine Treatment.
• Migraine key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Migraine Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Migraine market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Migraine drugs and therapies
https://www.delveinsight.com/sample-request/migraine-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Migraine Pipeline Market Drivers
• Increasing prevalence of Migraine, significant progress is being made in the preventative treatment of chronic migraine, growing awareness regarding migraine are some of the important factors that are fueling the Migraine Market.

Migraine Pipeline Market Barriers
• However, lack of proper diagnosis, various side-effects associated with the available drugs and other factors are creating obstacles in the Migraine Market growth.

Scope of Migraine Pipeline Drug Insight
• Coverage: Global
• Key Migraine Companies: Eli Lilly and Company, Satsuma Pharmaceuticals, Pulmatrix, Vaxxinity, Inc., Tonix Pharmaceuticals, Inc, AEON Biopharma, Inc., Axsome Therapeutics, Pfizer, and others
• Key Migraine Therapies: LY3451838, STS-101, PUR-3100, UB-313, TNX-1900, ABP-450, AXS 07, Zavegepant, and others
• Migraine Therapeutic Assessment: Migraine current marketed and Migraine emerging therapies
• Migraine Market Dynamics: Migraine market drivers and Migraine market barriers

Request for Sample PDF Report for Migraine Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/migraine-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Migraine Report Introduction
2. Migraine Executive Summary
3. Migraine Overview
4. Migraine- Analytical Perspective In-depth Commercial Assessment
5. Migraine Pipeline Therapeutics
6. Migraine Late Stage Products (Phase II/III)
7. Migraine Mid Stage Products (Phase II)
8. Migraine Early Stage Products (Phase I)
9. Migraine Preclinical Stage Products
10. Migraine Therapeutics Assessment
11. Migraine Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Migraine Key Companies
14. Migraine Key Products
15. Migraine Unmet Needs
16 . Migraine Market Drivers and Barriers
17. Migraine Future Perspectives and Conclusion
18. Migraine Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Migraine Market https://www.delveinsight.com/report-store/migraine-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Migraine Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Migraine Epidemiology https://www.delveinsight.com/report-store/migraine-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Migraine Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Orthopedic Trauma Devices Market https://www.delveinsight.com/report-store/orthopedic-trauma-devices-market
Global Orthopedic Trauma Devices Market was valued at USD 7.01 billion in 2023, growing at a CAGR of 6.43% during the forecast period from 2024 to 2030 to reach USD 10.15 billion by 2030. The demand for orthopedic trauma devices is witnessing growth due to the rising number of accident and trauma cases, growing prevalence of degenerative bone disorders, the rising number of sports-related injuries, rising demand for technologically advanced products, and increasing geriatric population are expected to drive product demand in the global orthopedic trauma devices market.

Acute Ischemic Stroke Market
https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
DelveInsight's 'Acute Ischemic Stroke Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of acute ischemic stroke in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Advanced Wound Care Market
https://www.delveinsight.com/report-store/advanced-wound-care-market
As per DelveInsight, the global Advanced Wound Care Market was valued at USD 10.44 billion in 2023, growing at a CAGR of 10.82% during the forecast period from 2024 to 2030, to reach USD 19.29 billion by 2030. The demand for advanced wound care is predominantly associated with the rising incidence of chronic wounds associated with various chronic disorders such as diabetes, and cancer, and also with the rising incidence of active wounds comprising burns, and surgical wounds, among others

Alcohol Use Disorder Market
https://www.delveinsight.com/report-store/alcohol-use-disorder-market
DelveInsight's "Alcohol Use Disorder (AUD) Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of AUD, historical and forecasted epidemiology, as well as the AUD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Congestive Heart Failure Market
https://www.delveinsight.com/report-store/congestive-heart-failure-market
DelveInsight's "Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of CHF, historical and forecasted epidemiology as well as the CHF market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

CDMO Market
https://www.delveinsight.com/report-store/contract-development-manufacturing-organization-market
Global CDMO market was valued at USD 100.02 billion in 2021, growing at a CAGR of 6.25% during the forecast period from 2024 to 2030, in order to reach USD 143.87 billion by 2030. Factors such as rising prevalence of various chronic and acute diseases leading to growing requirement of drugs, rising popularity of biologics as a treatment option are further expected to drive the demand for services offered by CDMOs as biologics being more complex than small molecules require elaborate facilities for product development.

Duchenne Muscular Dystrophy Market
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market
DelveInsight's "Duchenne Muscular Dystrophy Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Duchenne Muscular Dystrophy historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Generalized Myasthenia Gravis Market
https://www.delveinsight.com/report-store/generalized-myasthenia-gravis-gmg-market
DelveInsight's 'Generalized Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the Generalized Myasthenia Gravis, historical and forecasted epidemiology as well as the market trends in the United States, EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Glioblastoma Market
https://www.delveinsight.com/report-store/glioblastoma-market
DelveInsight's "Glioblastoma Market Insights, Epidemiology and Market Forecast- 2032" report delivers an in-depth understanding of the Glioblastoma, historical and forecasted epidemiology as well as the Glioblastoma market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Sickle Cell Disease Market
https://www.delveinsight.com/report-store/sickle-cell-disease-6mm-market
DelveInsight's "Sickle Cell Disease Market Insights, Epidemiology and Market Forecast- 2032" report delivers an in-depth understanding of the Sickle Cell Disease, historical and forecasted epidemiology as well as the Sickle Cell Disease market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. Among the 6MM countries the Sickle cell disease market size was valued ~USD 650 million in 2023 and is expected to increase throughout the forecast period (2024-2034).

Holter Monitor Market
https://www.delveinsight.com/report-store/holter-monitor-market
The Global Holter Monitor market will grow at a CAGR of 6.13% during the forecast period from 2024 to 2030. The stellar growth observed in the market is primarily due to the growing burden of various cardiovascular disorders which leads to abnormal heart rhythm such as atrial fibrillation, and heart palpitations, among others that may require monitoring through Holter monitors.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.